Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.9
Journals
TropicalMed
Special Issues
Antiviral Drug Resistance: From Mechanisms to Clinical Therapy
share announcement

Antiviral Drug Resistance: From Mechanisms to Clinical Therapy

A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Infectious Diseases".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 13030

Special Issue Editor

Dr. Ivana Grgic

E-Mail
Guest Editor
Department of Immunological and Molecular Diagnostics, University Hospital for Infectious Diseases “Dr. Fran Mihaljevic”, 10000 Zagreb, Croatia
Interests: infectious diseases; viral infections; molecular diagnostic; viral drug resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Every year, new viruses are being identified as etiologic agents of human diseases and, without efficient antiviral therapy, can be lethal. Direct acting antivirals have changed the way we deal with viral infections. There are more than 50 drugs approved for human use against viruses, such as HSV, HIV-1, CMV, the influenza virus, HBV, and HCV. Therapy for HIV infection has demonstrated how antivirals can impact the outcome of a lethal and chronic infection and extend life expectancy, while the treatment of HCV infection with direct acting antivirals is a good example of what is needed for reaching a sustained virological response. These lessons could be useful to further improve research for treating many other viral diseases in the future since the development of new antiviral drugs is very much a work in progress, with active drug discovery programs for filoviruses, coronaviruses, dengue, and others. In the past, the primary focus for drug development has been viral enzymes, but targeting host cellular activities necessary for viral entry and replication can also be a good strategy. Finally, the repurposing of drugs already approved for human use to target a whole spectrum of viruses instead of one could save time and money. However, viruses can easily adapt to any therapy; therefore, the resistance to antiviral drugs should be intensely studied.

In this Special Issue, our aim is to emphasize the need to closely inspect drug resistance, in order to improve the methods for establishing which mutations cause it, as well as new, easily performed, largely available, and cost-effective tests. The ongoing coronavirus pandemic, as well as many other potential threats, calls for new treatment solutions; however, monitoring the development of resistance mutations is essential if we want to be one step ahead of the virus.

Dr. Ivana Grgic
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiviral therapy
  • direct acting antivirals
  • drug resistance testing
  • HIV drug resistance
  • HCV drug resistance
  • HBV drug resistance
  • CMV drug resistance
  • HSV drug resistance

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 570 KiB  
Article
Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
by Nahed Mohammed Hawsawi, Tamer Saber, Hussein M. Salama, Walaa S. Fouad, Howaida M. Hagag, Hayaa M. Alhuthali, Emad M. Eed, Taisir Saber, Khadiga A. Ismail, Hesham H. Al Qurashi, Samir Altowairqi, Mohmmad Samaha and Dalia El-Hossary
Trop. Med. Infect. Dis. 2023, 8(2), 92; https://doi.org/10.3390/tropicalmed8020092 - 30 Jan 2023
Viewed by 2407
Abstract
Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including [...] Read more.
Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arabia, followed by genotype 1. The HCV genotype affects the response to different HCV treatments and the progression of liver disease. Currently, combinations of direct-acting antiviral drugs (DAAs) approved for the treatment of HCV achieve high cure rates with minimal adverse effects. Because real-world data from Saudi Arabia about the efficacy of DAAs are still limited, this study was conducted to assess the effectiveness of DAAs in treating patients with chronic hepatitis C and to identify the variables related to a sustained virologic response (SVR) in a real-world setting in Saudi Arabia. This prospective cohort study included 200 Saudi patients with chronic HCV who were 18 years of age or older and had been treated with DAAs at King Abdul-Aziz Specialized Hospital in Taif, Saudi Arabia, between September 2018 and March 2021. The response to treatment was assessed by whether or not an SVR had been achieved at week 12 post treatment (SVR12). An SVR12 was reached in 97.5% of patients. SVR12 rates were comparable for patients of different ages, between men and women, and between patients with and without cirrhosis. In addition, the SVR12 rates did not differ according to the infecting HCV genotype. In this study, the presence of cirrhosis and the patient’s gender were independent predictors of who would not reach an SVR12 (known here as the non-SVR12 group) according to the results of univariate and multivariate binary logistic regression analyses based on the determinants of SVR12. In this population of patients with chronic HCV infection, all DAA regimens achieved very high SVR12 rates. The patients’ gender and the presence of cirrhosis were independent factors of a poor response. Full article
(This article belongs to the Special Issue Antiviral Drug Resistance: From Mechanisms to Clinical Therapy)
►▼ Show Figures

Figure 1

13 pages, 446 KiB  
Article
Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients
by Seham Mahrous Zaki, Hanan Samir Ahmed, Monkez Motieh Yousif and Eman Mohamed Awad
Trop. Med. Infect. Dis. 2022, 7(9), 230; https://doi.org/10.3390/tropicalmed7090230 - 05 Sep 2022
Cited by 2 | Viewed by 1757
Abstract
In various genome-wide correlation studies, interleukin (IL)28B gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distributions of IL28B (rs12979860) in patients [...] Read more.
In various genome-wide correlation studies, interleukin (IL)28B gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distributions of IL28B (rs12979860) in patients with chronic hepatitis C and assess the IL28B polymorphisms as predictors of sustained virological response to SOF-based therapy for HCV in Egyptian patients. This retrospective case-control study was conducted on 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and responded to treatment with SVR12 (the responder group) as a control group, and 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and did not respond to treatment and failed to achieve SVR12 (the non-responder group) as a case group. The CC genotype frequency of IL-28B (rs12979860) was greater in the responder group (51.9%). In contrast, the TT genotype frequency was higher in the non-responder group (48.1%) (p < 0.001), and the T allele significantly increased the risk of non-responses by 3.13 fold. Therefore IL-28B (rs12979860) SNP could be used as a genetic predictor of sustained virological response to SOF+DCV ± RBV-based HCV treatment in Egyptian patients. Full article
(This article belongs to the Special Issue Antiviral Drug Resistance: From Mechanisms to Clinical Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 2171 KiB  
Review
Current Trends and Limitations in Dengue Antiviral Research
by Juliet O. Obi, Hernando Gutiérrez-Barbosa, Joel V. Chua and Daniel J. Deredge
Trop. Med. Infect. Dis. 2021, 6(4), 180; https://doi.org/10.3390/tropicalmed6040180 - 30 Sep 2021
Cited by 44 | Viewed by 8175
Abstract
Dengue is the most prevalent arthropod-borne viral disease worldwide and affects approximately 2.5 billion people living in over 100 countries. Increasing geographic expansion of Aedes aegypti mosquitoes (which transmit the virus) has made dengue a global health concern. There are currently no approved [...] Read more.
Dengue is the most prevalent arthropod-borne viral disease worldwide and affects approximately 2.5 billion people living in over 100 countries. Increasing geographic expansion of Aedes aegypti mosquitoes (which transmit the virus) has made dengue a global health concern. There are currently no approved antivirals available to treat dengue, and the only approved vaccine used in some countries is limited to seropositive patients. Treatment of dengue, therefore, remains largely supportive to date; hence, research efforts are being intensified for the development of antivirals. The nonstructural proteins, 3 and 5 (NS3 and NS5), have been the major targets for dengue antiviral development due to their indispensable enzymatic and biological functions in the viral replication process. NS5 is the largest and most conserved nonstructural protein encoded by flaviviruses. Its multifunctionality makes it an attractive target for antiviral development, but research efforts have, this far, not resulted in the successful development of an antiviral targeting NS5. Increase in structural insights into the dengue NS5 protein will accelerate drug discovery efforts focused on NS5 as an antiviral target. In this review, we will give an overview of the current state of therapeutic development, with a focus on NS5 as a therapeutic target against dengue. Full article
(This article belongs to the Special Issue Antiviral Drug Resistance: From Mechanisms to Clinical Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop